Abstract 779
Background
The prognosis of patients with inoperable lower esophageal cancers remains poor with only option being concurrent chemo-radiation. Among the various agents available, there is no study done focusing on TWISTT score and QOL in southern Indian population.
Methods
This is a single-centre, two arm, retrospective analysis evaluating 75 patients with histologically confirmed inoperable adenocarcinoma esophagus lower 1/3rd who are on definitive chemoradiation. The patients were administered IV cisplatin 40 mg/m2 weekly IV (n = 38) as per institutional protocol vs Capecitabine 800 mg/m2 PO (n = 37) twice a day along with radiotherapy of 6600-7000 cGy over 35 fractions. Patients were evaluated over response evaluation criteria in solid tumors (RECIST) criteria 12 weeks after the last cycle of chemotherapy as well as for TWISTT score and QOL.
Results
The median duration of follow up was 20 months. Objective Response Rate (ORR) was observed in 84.2% of the patients with patients in the Cisplatin arm vs 86.4% in Capecitabine arm. There are no differences in the complete response (CR) and partial response (PR) rates in the two arms. The median overall survival was 20.7 months (95% CI: 18.8-, 28.7) in cisplatin arm vs 22.7 months (95% CI: 20.2-, 30.2). The median TWISTT score in Cisplatin was 246 days vs 228 days for capecitabine. The median QOL was similar in both arms.
Conclusions
Capecitabine vs Cisplatin along with concurrent radiotherapy had similar overall response rates and progression free survival with similar TWISTT score and QOL and either can be used for concurrent therapy based on physician/ patient preferences.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Goutham.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5553 - Cytokine genetic variations and worse quality of life among family caregivers of head and neck cancer patients in palliative care
Presenter: Daniel Pequeno
Session: Poster Display session 1
Resources:
Abstract
4321 - Health-related quality of life of advanced melanoma survivors treated with CTLA-4 immune checkpoint inhibition: a matched cohort study
Presenter: Annelies Boekhout
Session: Poster Display session 1
Resources:
Abstract
5914 - Cancer, Mental Health and End Life Simulation (CAMhELS): A novel effectiveness evaluation.
Presenter: Asanga Fernando
Session: Poster Display session 1
Resources:
Abstract
2597 - Cancer patients’ expectations and understanding about their disease
Presenter: Mónica Pinho
Session: Poster Display session 1
Resources:
Abstract
5187 - Impact of patients’ death on oncologists and coping strategies: An online survey
Presenter: Soumaya Labidi
Session: Poster Display session 1
Resources:
Abstract
4579 - Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre
Presenter: Andrea Sbrana
Session: Poster Display session 1
Resources:
Abstract
5058 - Preparedness for caregiving in caregivers of cancer patients
Presenter: Hatice Yakar
Session: Poster Display session 1
Resources:
Abstract
5917 - Oncologic Emergency Medicine in the real world: A survey and proposal for improvement
Presenter: Carintia Dorta Pérez
Session: Poster Display session 1
Resources:
Abstract
4077 - The Reality of Critical Cancer Patients in a Polyvalent Intensive Care Unit
Presenter: Tiago Filipe Da Cruz Tomas
Session: Poster Display session 1
Resources:
Abstract
1728 - A phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE Study
Presenter: Hironobu Hashimoto
Session: Poster Display session 1
Resources:
Abstract